Medical devices, healthcare technology and the business of care
PMA SUPPLEMENT · P110020/S043

cobsa BRAF V600 Mutation Test

Roche Molecular Systems, Inc. · Decision date Dec 31, 2025

FDA DECISIONP110020/S043

What did the FDA decide?

FDA records P110020/S043 as a supplement to PMA P110020, with the supplement type “30-Day Notice”. The recorded decision is OK30 (30-day notice), dated Dec 31, 2025.

FDA approval order statement

changes to QC testing of filters used in reagent manufacturing
Regulatory pathway
PMA supplement
Supplement type
30-Day Notice
Clinical specialty
Pathology
Decision date
Dec 31, 2025
FDA change category
Process Change - Manufacturer/Sterilizer/Packager/Supplier

FDA source record

Regulatory record facts

Identifier
P110020/S043
Regulatory pathway
PMA supplement
Product code
OWD
Decision code
OK30
Decision date
Dec 31, 2025
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: Somatic gene mutation detection system.

Product code
OWD
FDA device class
3

For the original device and its historical approval scope, see PMA P110020. Subsequent supplements may change the device or its indications.

FDA decision timeline

  1. P110020 · Original PMA

    COBAS 4800 BRAF V600 MUTATION TEST

  2. P110020/S043 received

    Application receipt date recorded by FDA.

  3. P110020/S043 · FDA decision

    30-Day Notice

  4. P110020/S044 · Related supplement

    cobas BRAF V600 Mutation Test

  5. P110020/S045 · Related supplement

    cobas BRAF V600 Mutation Test

  6. P110020/S046 · Related supplement

    Roche cobas BRAF V600 Mutation Test

Timeline entries are records held by MedtechLedger for P110020. View FDA’s full supplement list.

Related devices and submissions

Same PMA: P110020

Product / regulatory recordCompanyPathwayDecision dateSource
Roche Molecular Systems, Inc.PMA approvalAug 17, 2011FDA
Roche Molecular Systems, Inc.PMA supplementMar 17, 2026FDA
Roche Molecular Systems, Inc.PMA supplementOct 27, 2026FDA
Roche Molecular Systems, Inc.PMA supplementNov 4, 2026FDA

Explore the linked device profile

Other records with product code OWD

Product / regulatory recordCompanyPathwayDecision dateSource
RochePMA supplementNov 4, 2026FDA
Roche Molecular Systems, Inc.PMA supplementNov 4, 2026FDA
RochePMA supplementOct 27, 2026FDA
Roche Molecular Systems, Inc.PMA supplementOct 27, 2026FDA
Roche Molecular System, Inc.PMA supplementOct 27, 2026FDA

A shared product code identifies a classification relationship; it does not establish clinical equivalence.

Regulatory context

A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

Roche Molecular Systems, Inc.

Headquarters
Not reported
Brand website
roche.com
FDA applicant address
4300 Hacienda Dr., Pleasanton, CA, 94588

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records